Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Subjects

Xiao Zhang1 Department of Rheumatology, Guangdong General Hospital, Guangdong, People’s Republic of ChinaView further author information

Huji Xu2 Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, People’s Republic of China

https://orcid.org/0000-0002-8588-118X View further author information

Zhiyi Zhang3 School of Clinical Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of ChinaView further author information

Yang Li4 Department of Rheumatology and Immunology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of ChinaView further author information

Lynne Pauer5 Global Research and Development, Pfizer, Groton, CT, USAView further author information

Shanmei Liao6 Pfizer China Statistics Department, Global Innovative Pharma Business, Shanghai, People’s Republic of ChinaView further author information

Fengchun Zhang7 Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information

show all

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Subjects

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Subjects

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date